Pyrosequencing of the BRAFV600E Mutation

计划入组 101 人 · 首次发布于 2007 年 10 月 31 日

Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma

计划入组 53 人 · 首次发布于 2015 年 9 月 28 日

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

计划入组 131 人 · 首次发布于 2011 年 1 月 7 日

Correction of Q347X mutation(Beam Therapeutics)

KRAS mutation G12D-targeted ONCOlogues ( Oncogenuity)

Personalized Mutation-derived Tumor Vaccine(NovoCure)

Cogent Biosciences

United States

Nuvation Bio

United States

FONDS DE DOTATION HTC PROJECT

France

European Commission Approves Encorafenib and Binimetinib Combination for BRAF V600E-Mutant NSCLC

Ono Pharmaceutical Secures Approvals for BRAFTOVI Combination Therapy in BRAF-Mutant Colorectal Cancer

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment for BRAFV600E-Mutant Metastatic Colorectal Cancer